Evidence map›Paper›PMID 32536058›Full record

ArticleZhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology2020

[Effect of sorafenib and prophylactic TACE for prevention of postoperative relapse in patients with liver cancer combined with microvascular invasion].

P C Shen, Z Q Gao, D Y Li, Z Tang

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 3 pooled it
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 syntheses or guidelines pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

P C ShenHepatological Surgery Department, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, China.
Z Q GaoHepatological Surgery Department, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, China.
D Y LiHepatological Surgery Department, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, China.
Z TangHepatological Surgery Department, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, China.
First Affiliated Hospital of Zhengzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antineoplastic AgentsCarcinoma, HepatocellularChemoembolization, TherapeuticLiver NeoplasmsSorafenibHepatectomyHumansNeoplasm InvasivenessNeoplasm Recurrence, LocalRetrospective StudiesTreatment OutcomeAntineoplastic AgentsSorafenibHepatocellular carcinomaMicrovascular invasionSorafenibTranscatheter arterial chemoembolizationTumor-free survival rate

Identifiers

PMID32536058
PMCPMC12770044
OpenAlexW3034258804

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.